WuXi Biologics (Cayman)

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption (abre em uma nova aba)

  GlobeNewswire · 1 de out. de 2026

• 
  WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability (abre em uma nova aba)

  PR Newswire · 24 de set. de 2026

• Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong (abre em uma nova aba)

  富途牛牛 · 24 de set. de 2026

• 
  WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership (abre em uma nova aba)

  PR Newswire · 16 de set. de 2026

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (abre em uma nova aba)

  14 de set. de 2026

• 
  WuXi Biologics Reports Strong Profitable Growth in H1 2026 (abre em uma nova aba)

  PR Newswire · 25 de ago. de 2026

• 
  WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO (abre em uma nova aba)

  PR Newswire · 18 de ago. de 2026

• 
  Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition? (abre em uma nova aba)

  Simply Wall St. · 31 de jul. de 2026

• 
  WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO (abre em uma nova aba)

  PR Newswire · 29 de jul. de 2026

• 
  WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (abre em uma nova aba)

  PR Newswire · 9 de jul. de 2026

• 
  WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year (abre em uma nova aba)

  PR Newswire · 8 de jul. de 2026

• 
  WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy (abre em uma nova aba)

  PR Newswire · 30 de jun. de 2026

• WuXi Biologics on target for 2028 opening in Worcester (abre em uma nova aba)

  29 de jun. de 2026

• 
  WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations (abre em uma nova aba)

  PR Newswire · 24 de jun. de 2026

• 
  WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards (abre em uma nova aba)

  PR Newswire · 8 de jun. de 2026

• WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility (abre em uma nova aba)

  5 de jun. de 2026

• WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year (abre em uma nova aba)

  3 de jun. de 2026

• WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing (abre em uma nova aba)

  26 de mai. de 2026

• WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index (abre em uma nova aba)

  13 de mai. de 2026

• Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness (abre em uma nova aba)

  11 de mai. de 2026